Measles elimination in the Americas: A comparison between countries with a one-dose and two-dose routine vaccination schedule

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 2, 2011, Pages

  Sever, Adrianne E ^a,b   Rainey, Jeanette J ^b   Zell, Elizabeth R ^c   Hennessey, Karen ^b   Uzicanin, Amra ^b   Castillo Solórzano, Carlos ^d   Dietz, Vance ^b  

^a Office of Workforce and Career Development   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d PAN AMERICAN HEALTH ORGANIZATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

ADOLESCENT; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; EDUCATION; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFANT MORTALITY; INFECTION CONTROL; INFECTION SENSITIVITY; MEASLES; MEASLES VACCINATION; POPULATION DENSITY; PRIORITY JOURNAL; URBAN POPULATION; INFECTION RISK; KAPLAN MEIER METHOD; PROPENSITY SCORE; READING; SOCIOECONOMICS; WESTERN HEMISPHERE;

ADOLESCENT; CENTRAL AMERICA; CHILD; COMMUNICABLE DISEASE CONTROL; DISEASE SUSCEPTIBILITY; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEASLES; MEASLES VACCINE; NATIONAL HEALTH PROGRAMS; RISK FACTORS; SOCIOECONOMIC FACTORS; SOUTH AMERICA; VACCINATION;

EID: 80053404335     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir445     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Progress in global measles control and mortality reduction, 2000-2007. MMWR. Morb Mortal Wkly Rep 2008; 57:1303-6.
2. Duke T, Mgone CS. Measles: not just another viral exanthem. Lancet 2003; 361:763-73. (Pubitemid 36293634)
3. Tulchinsky TH, Ginsberg GM, Abed Y, Angeles MT, Akukwe C, Bonn J. Measles control in developing and developed countries: the case for a two-dose policy. Bull World Health Organ 1993; 71:93-103. (Pubitemid 23075967)
4. Markowitz LE, Orenstein WA. Measles vaccines. Pediatr Clin North Am 1990; 37:603-25. (Pubitemid 20196037)
5. Hinman AR, Orenstein WA, Papania MJ. Evolution of measles elimination strategies in the United States. J Infect Dis 2004; 189(Suppl 1): S17-S22. (Pubitemid 38639563)
6. Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 2004; 189(Suppl 1):S27-S35. (Pubitemid 38639565)
7. Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis 2004; 189(Suppl 1):S116-S122. (Pubitemid 38639579)
8. Rosenthal SR, Clements CJ. Two-dose measles vaccination schedules. Bull World Health Organ 1993; 71:421-8. (Pubitemid 23200087)
9. Centers for Disease Control and Prevention. Progress toward elimination of measles and prevention of congenital rubella infection-European region, 1990-2004. MMWR Morb Mortal Wkly Rep 2005; 54:175-8.
10. Orenstein WA, Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL. Measles eradication: is it in our future? Am J Public Health 2000; 90:1521-5.
11. Christenson B, Böttiger M. Changes of the immunological patterns against measles, mumps and rubella: a vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule. Vaccine 1991; 9:326-9.
12. Johnson CE, Kumar ML, Whitwell JK, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J 1996; 15:687-92. (Pubitemid 26271977)
13. Stetler HC, Orenstein WA, Bernier RH, et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics 1986; 77:471-6. (Pubitemid 16104457)
14. de Quadros CA, Andrus JK, Danovaro-Holliday MC, Castillo-Solórzano C. Feasibility of global measles eradication after interruption of transmission in the Americas. Expert Rev Vaccines 2008; 7:355-62. (Pubitemid 351520023)
15. de Quadros CA. Is global measles eradication feasible? Curr Top Microbiol Immunol 2006; 304:153-63.
16. Orenstein WA, Hinman AR, Strebel PJ. Measles: the need for 2 opportunities for prevention. Clin Infect Dis 2006; 42:320-1. (Pubitemid 43122304)
17. Hersh BS, Tambini G, Nogueira AC, Carrasco P, de Quadros CA. Review of regional measles surveillance data in the Americas, 1996-99. Lancet 2000; 355:1943-8. (Pubitemid 30326098)
18. de Quadros CA, Olivé JM, Hersh BS, et al. Measles elimination in the Americas: evolving strategies. JAMA 1996; 275:224-9.
19. de Quadros CA, Izurieta H, Venczel L, Carrasco P.Measles eradication in the Americas: progress to date. J Infect Dis 2004; 189(Suppl 1):S227-35. (Pubitemid 38639595)
20. World Health Organization, United Nations Children's Fund. Increasing immunization coverage at the health facility level. Vaccines and biologicals. Geneva: World Health Organization, 2002.
21. Pan American Health Organization (PAHO). PAHO basic indicators database. Washington, DC: PAHO, 2008. http://www.paho.org/English/SHA/coredata/tabulator/ newTabulator.htm. Accessed 14 December 2007.
22. United Nations Educational, Scientific, and Cultural Organization (UNESCO). UNESCO institute for statistics data centre. Vol 2008. Paris: UNESCO, 2008. http://stats.uis.unesco.org/unesco/Table Viewer/document.aspx? ReportId5143&IF-Language5eng. Accessed 16 December 2007.
23. Anand S, Bärnighausen T. Health workers and vaccination coverage in developing countries: an econometric analysis. Lancet 2007; 369: 1277-85. (Pubitemid 46553847)
24. Anand S, Bärnighausen T. Human resources and health outcomes: cross-country econometric study. Lancet 2004; 364:1603-9. (Pubitemid 39446384)
25. Bondy JN, Thind A, Koval JJ, Speechley KN. Identifying the determinants of childhood immunization in the Philippines. Vaccine 2009; 27:169-75.
26. Robinson J, Wharrad H. Invisible nursing: exploring health outcomes at a global level. Relationships between infant and under-5 mortality rates and the distribution of health professionals, GNP per capita, and female literacy. J Adv Nurs 2000; 32:28-40.
27. SchellCO, ReillyM, Rosling H, Peterson S, EkströmAM. Socioeconomic determinants of infant mortality: a worldwide study of 152 low-,middle-, and high-income countries. Scand J Public Health 2007; 35:288-97. (Pubitemid 47386433)
28. Marin M, Nguyen HQ, Langidrik JR, et al. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clin Infect Dis 2006; 42:315-9. (Pubitemid 43122303)
29. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003; 158: 280-7. (Pubitemid 36944422)
30. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
31. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127:757-63. (Pubitemid 27446562)
32. Clogg CC, Rubin DB, Schenker N, Schultz B, Weidman L. Multiple imputation of industry and occupational codes in census public-use samples using Bayesian Logistic. Regression. J Am Stat Assoc 1991; 86:68-78.
33. Allison PD. Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute, 1995.
34. Pan American Health Organization (PAHO). Revolving fund for vaccine procurement. Washington, DC: PAHO, 2008. http://www.paho.org/english/hvp/hvi/ revol-fund.htm Accessed 7 May 2008.
35. Williams BG, Cutts FT, Dye C. Measles vaccination policy. Epidemiol Infect 1995; 115:603-21. (Pubitemid 26025335)
36. Centers for Disease Control and Prevention. Progress toward measles mortality reduction and elimination-Eastern Mediterranean Region, 1997-2007. MMWR Morb Mortal Wkly Rep 2008; 57:262-7.
37. Belmaker I, Bazarsky E, Dukhan L, Shlomo C, Rager-Zisman B. Twodose measles immunization as a strategy to eliminate measles in the Middle East and Israel. Isr Med Assoc J 2008; 10:640-5.